Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like
Incyte (INCY) shares dropped 7% last week, following a Q4 2025 earnings report that saw revenue beat estimates but adjusted EPS and 2026 product revenue guidance fall short. This guidance shortfall, particularly for Opzelura, raises concerns about the company's ability to offset Jakafi's upcoming patent expiration in 2028 with new pipeline assets. Despite a strong pipeline and positive analyst sentiment for long-term growth, the market is now pricing in execution risk for Incyte’s transition away from Jakafi, with its current valuation appearing fair to slightly stretched.
AHA, ACC issue guidelines for pulmonary embolism that affect Boston Scientific, Stryker
New guidelines from the American Heart Association (AHA) and American College of Cardiology (ACC) for pulmonary embolism (PE) could significantly benefit Boston Scientific and Stryker, particularly their mechanical thrombectomy (MT) systems. The updated guidelines, the first since 2011, introduce a new classification scheme for PE severity and assign a higher level of evidence for MT use, maintaining its recommendation for massive and submassive PE. Analysts believe this update, which includes detailed categories for risk assessment and therapeutic decision-making, could boost both companies' market position.
Boston Scientific Stock is Down 20% This Year. Here Is What Investors Need to Know Before March 28
Boston Scientific (BSX) stock has declined significantly, trading near its 52-week low after a steep single-day drop due to Q4 EP sales missing estimates. Despite solid overall Q4 results, the market focused on perceived decelerations in key growth drivers, leading to analyst price target cuts. Investors are now looking to the CHAMPION trial readout on March 28 and the eventual Penumbra close as critical near-term catalysts that could reframe the company's growth story and potentially unlock significant upside from its currently undervalued price.
Medtronic to cut 81 employees at California diabetes site
Medtronic (NYSE:MDT) is laying off 81 employees at its Northridge, California diabetes device facility, effective April 7, 2026. This restructuring comes as the company prepares to spin out its diabetes business, MiniMed, into a standalone public entity. The affected roles include engineering, IT, marketing, and technician positions, with Medtronic stating the cuts are necessary to ensure the new company's long-term success.
BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
This article compares two MedTech companies, Boston Scientific (BSX) and Abbott (ABT), evaluating them as potential investments. It details each company's recent operational performance, strategic acquisitions, and financial metrics, including EPS estimates and price-to-sales ratios. While both are strong players in the MedTech sector with bullish analyst ratings, Abbott is presented as the more attractive option due to its current valuation and recent stock performance.
Neurosurgery Market Is Going to Boom |Medtronic, Stryker Corporation, Zimmer Biomet, Johnson & Johnson
The global neurosurgery market is projected to grow from USD 4.10 billion in 2026 to USD 5.69 billion by 2033, exhibiting a CAGR of 4.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report by Coherent Market Insights provides a comprehensive analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Pomerantz LLP is investigating potential securities fraud claims against Boston Scientific Corporation (BSX) following a significant drop in its stock price. This investigation stems from the company's release of fourth-quarter 2025 financial results, which showed lower-than-expected sales in its electrophysiology division. On February 4, 2026, Boston Scientific's stock fell by $16.12 per share, or 17.6%, closing at $75.50.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in Boston Scientific Corporation (BSX). This investigation follows a significant drop in Boston Scientific's stock price on February 4, 2026, after the company reported lower-than-expected sales in its electrophysiology division for the fourth quarter of 2025. Investors who suffered losses are encouraged to contact the law firm.
Danaher to Acquire Masimo in Transaction Valued at $9.9 Billion
Danaher Corporation has entered into a definitive agreement to acquire Masimo Corporation for $180 per share in cash, valuing the transaction at approximately $9.9 billion. Masimo, known for its pulse oximetry and patient monitoring technologies, will operate as a standalone company within Danaher’s Diagnostics segment upon closing. The acquisition is expected to enhance Danaher’s diagnostic capabilities and generate over $530 million in EBITDA for Masimo by 2027.
Do Integer’s Mixed 2025 Results and 2026 Guidance Reframe Its Profitability Story for ITGR Investors?
Integer Holdings reported higher Q4 2025 sales but lower full-year net income compared to the previous year, alongside new 2026 guidance. While Q4 earnings were strong, the overall 2025 profit was softer, and the 2026 outlook factors into ongoing investor concerns and a shareholder investigation. This creates a mixed narrative for investors regarding future profitability and growth sustainability.
Goldman Sachs Adjusts Boston Scientific Price Target to $98 From $99, Maintains Buy Rating
Goldman Sachs has adjusted its price target for Boston Scientific (BSX) to $98, down from $99, while reaffirming a Buy rating on the stock. This update reflects a minor revision in the analyst's valuation, despite ongoing positive sentiment for the medical equipment company.
Cardio Diagnostics Announces Investor Call Amidst Strategic Growth Plans
Cardio Diagnostics Holdings Inc. (CDIO) is holding an investor call to discuss strategic growth initiatives, including advancements in its AI-backed precision cardiovascular test. Despite reporting a net loss of $1.71M, the company maintains a robust 100% gross margin and a low debt-to-equity ratio of 0.03. The call aims to boost investor confidence and align narratives regarding the company's future in the evolving healthcare technology market.
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
Boston Scientific (NYSE: BSX) is acquiring Penumbra, Inc. (NYSE: PEN) for $14.5 billion, a move that will reshape the medtech industry by positioning Boston Scientific as a dominant player in neurovascular and thrombectomy markets. This acquisition, structured as 73% cash and 27% stock, signals a strategic return to the neurovascular space for Boston Scientific and highlights a broader trend of consolidation and "Industrialization" within the medical technology sector. The deal is expected to create a duopoly with Stryker in the mechanical thrombectomy market, putting pressure on competitors like Medtronic.
L & S Advisors Inc Grows Holdings in Boston Scientific Corporation $BSX
L & S Advisors Inc increased its stake in Boston Scientific Corporation by 26.3% in the third quarter, bringing its total holdings to 91,029 shares valued at $8,887,000. Other hedge funds and institutional investors also adjusted their positions in BSX. Insider transactions show EVP Arthur C. Butcher and CEO Michael F. Mahoney selling shares in separate transactions, while analysts have issued various ratings and price targets for the medical equipment provider.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its critical role in drug development, personalized medicine, and biotech research. Key technologies include X-ray crystallography, NMR, and cryo-EM, with North America currently dominating and Asia-Pacific showing rapid growth due to increased R&D and AI integration. Challenges like high equipment costs and a shortage of skilled personnel persist, but technological advancements and strategic investments are propelling market expansion.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its crucial role in drug development, personalized medicine, and biotech research. Key technologies like X-ray crystallography, NMR, and cryo-EM are central to this growth, with North America currently dominating and Asia-Pacific showing rapid expansion. The market faces challenges such as high equipment costs and a shortage of skilled personnel, but technological advancements and strategic investments are propelling its forward trajectory.
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices
The global market for Negative Pressure Wound Therapy (NPWT) devices is projected to grow from $2.9 billion in 2025 to $3.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This growth is driven by the increasing demand for advanced wound healing technologies, particularly for managing diabetic foot ulcers and surgical site infections. The report analyzes market trends, applications, end-users, and regional dynamics, profiling major companies such as Solventum and Smith+Nephew.
The 5 Most Interesting Analyst Questions From DexCom's Q4 Earnings Call
DexCom's Q4 2025 earnings call highlighted strong performance, driven by the G7 15-day sensor system and international expansion. Analysts focused on long-term growth prospects, Medicare coverage for type two non-insulin users, the G7 sensor's margin contributions, and factors influencing revenue growth guidance. Management expressed optimism about future expansion and continued high utilization rates.
Boston Scientific Tests Combined Cardiac Devices In OPTION EMEA Trial
Boston Scientific has initiated the OPTION-EMEA clinical trial across Europe to evaluate the combined use of its FARAPULSE pulsed field ablation system and WATCHMAN left atrial appendage closure device for patients with atrial fibrillation and stroke prevention. This trial aims to assess the safety and benefits of this combined therapy in real-world hospital settings. The success of this trial could significantly strengthen Boston Scientific's position in atrial fibrillation care and expand the use of its cardiac therapies, offering potential upsides for investors despite recent stock declines.
Medtronic plc (NYSE:MDT) Q3 2026 Earnings Call Transcript
Medtronic plc reported strong Q3 2026 earnings, exceeding expectations with 6% organic revenue growth and EPS of $1.36. The company highlighted significant progress in its four generational growth drivers: PFA platform for AFib, Symplicity Spyral for hypertension, Altaviva for urinary incontinence, and the Hugo surgical robot. Medtronic reaffirmed its fiscal 2026 organic revenue growth guidance of approximately 5.5% and committed to high single-digit EPS growth for fiscal year 2027, driven by accelerated growth and strategic investments.
May Hill Capital LLC Sells 24,240 Shares of Boston Scientific Corporation $BSX
May Hill Capital LLC reduced its stake in Boston Scientific Corporation by 40% in Q3 2025, selling 24,240 shares and retaining 36,433 shares valued at approximately $3.56 million. This move makes Boston Scientific its 21st largest holding, representing about 1% of the fund's portfolio. Several Boston Scientific insiders also made significant share sales, while the company reported beating Q4 EPS estimates and provided Q1 and FY 2026 guidance, maintaining a "Moderate Buy" consensus rating among analysts despite some price target trims.
Medtronic plc Q3 FY2026 Earnings: Revenue Hits $9.0B With Highest Enterprise Growth in 10 Quarters
Medtronic plc reported stronger-than-expected Q3 FY2026 earnings, with non-GAAP EPS of $1.36 and revenue of $9.017 billion, marking the highest enterprise growth in 10 quarters. Despite beating analyst estimates for both revenue and EPS, Medtronic's shares fell approximately 3.2% as the company reiterated its full-year guidance rather than raising it. The company's Cardiovascular portfolio saw significant growth, particularly in Cardiac Ablation Solutions, although GAAP net income declined due to increased expenses.
NEOS Investment Management LLC Buys 58,819 Shares of Boston Scientific Corporation $BSX
NEOS Investment Management LLC significantly increased its stake in Boston Scientific Corporation by 43.6%, acquiring an additional 58,819 shares. This comes amidst insider selling by CEO Michael F. Mahoney and EVP Arthur C. Butcher, although institutional investors and hedge funds still hold a substantial 89.07% of the company's stock. Despite several brokerages cutting price targets, Boston Scientific maintains a "Moderate Buy" consensus rating with a $108.36 average target, following a slight beat on quarterly EPS and positive FY2026 guidance.
Danaher buys patient monitoring specialist Masimo in $9.9B deal
Danaher Corporation has announced the acquisition of Masimo, a patient monitoring medtech company, for $9.9 billion. Masimo will operate as a standalone company within Danaher's diagnostics segment, strengthening Danaher's portfolio with advanced sensor technology and AI-enabled monitoring. This acquisition follows a period of challenges for Masimo, including a proxy fight and a legal battle with Apple over patent infringement, and is expected to accelerate growth for Danaher’s diagnostics segment.
Rare Earth Stock Tests Historically Bullish Trendline
MP Materials Corp (NYSE:MP) stock, despite sliding to a one-month low today, is considered technically resilient and is testing its ascending 200-day moving average. Historical data suggests a high probability of a significant price rebound within a month following similar setups, with analysts overwhelmingly bullish on the stock. However, a high short interest indicates a significant number of investors betting against the company.
Boston Scientific’s OPTION-EMEA Trial Targets One-Stop AF and Stroke Protection
Boston Scientific (BSX) is conducting the OPTION-EMEA clinical trial to assess the real-world outcomes of a combined procedure for patients with atrial fibrillation (AF) using their FARAPULSE PFA System and WATCHMAN FLX Pro or WATCHMAN FLX devices. This single-arm study aims to evaluate the practicality and safety of performing both AF treatment and stroke risk reduction in one visit. While the trial is still in the setup phase, successful outcomes could strengthen Boston Scientific's market position and potentially lead to increased adoption and revenue.
Vanguard Group Inc. Increases Stock Position in Becton, Dickinson and Company $BDX
Vanguard Group Inc. has increased its stake in Becton, Dickinson and Company (BDX) by 0.5% in the third quarter, now owning 32,455,790 shares valued at approximately $6.07 billion, representing 11.32% of the company. Despite beating quarterly earnings expectations with $2.91 EPS and $5.25 billion in revenue, Becton, Dickinson and Company provided conservative FY2026 guidance below analyst estimates. The company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan, while analysts maintain a "Hold" rating with an average target price of $195.46.
GSA Capital Partners LLP Has $1.86 Million Stake in Boston Scientific Corporation $BSX
GSA Capital Partners LLP increased its stake in Boston Scientific Corporation by 468.5% in the third quarter, acquiring an additional 15,687 shares to bring its total holdings to 19,035 shares, valued at approximately $1.86 million. This news comes as Boston Scientific reported strong Q4 2025 earnings, exceeding analyst expectations for both EPS and revenue, and provided optimistic guidance for Q1 and FY 2026. Despite insider stock sales by CEO Michael F. Mahoney and EVP Arthur C. Butcher, institutional investors collectively own a significant 89.07% of the company's stock.
Skandinaviska Enskilda Banken AB publ Buys 529,529 Shares of Boston Scientific Corporation $BSX
Skandinaviska Enskilda Banken AB publ increased its stake in Boston Scientific Corporation (NYSE:BSX) by 26.1% in the third quarter, acquiring an additional 529,529 shares. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also increased their positions. Analyst ratings for Boston Scientific are predominantly "Buy" or "Overweight," with a consensus target price of $109.43, despite recent price target reductions from several firms.
Public Sector Pension Investment Board Has $10.30 Million Stock Holdings in Acadia Realty Trust $AKR
The Public Sector Pension Investment Board increased its stake in Acadia Realty Trust ($AKR) by 14.5% to 511,079 shares, now valued at $10.30 million. This move makes them a significant institutional investor in the real estate investment trust. Despite missing EPS consensus, Acadia Realty Trust exceeded revenue expectations and maintains a "Hold" consensus rating from analysts with an average price target of $22.00.
M&G PLC Increases Holdings in Boston Scientific Corporation $BSX
M&G PLC significantly increased its stake in Boston Scientific (NYSE:BSX) by 449.1% in Q3, now owning 131,872 shares valued at approximately $12.92 million. This comes despite major insider selling by CEO Michael F. Mahoney and EVP Arthur C. Butcher. Boston Scientific also delivered strong Q4 2025 earnings, beating EPS estimates and reporting a 15.9% revenue increase year-over-year, alongside positive guidance for Q1 and FY 2026.
Intragastric Balloons Market to Reach $115.3 Million, Globally, by 2033 at 13.6% CAGR: Allied Market Research
The global intragastric balloons market, valued at $32.2 million in 2023, is projected to reach $115.3 million by 2033, growing at a CAGR of 13.6%. This growth is primarily driven by rising obesity rates, increased preference for non-surgical weight-loss options, and technological advancements. Key market segments include single intragastric balloons, saline-filled balloons, and hospitals as the main end-users, with North America leading in utilization and Asia-Pacific showing rapid growth.
Here are Updates on Alcon’s (ALC) Compensation and Sustainability Matters
Sustainable Growth Advisers (SGA) Emerging Markets Growth Strategy updated its investors on Alcon Inc. (NYSE: ALC), detailing discussions held with Alcon's leadership in December regarding compensation and sustainability. SGA addressed concerns about Alcon's 2025 performance impact on short-term incentives, advocated for incorporating Total Shareholder Return (TSR) and M&A effectiveness metrics, and noted Alcon's plans to adjust executive remuneration. The firm was pleased with Alcon's increased disclosure on Scope 3 emissions and carbon offsets, topics they had previously discussed.
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum
Medtronic (MDT) has transitioned from a stable but slow-moving company to a high-growth contender, driven by its revitalized cardiovascular portfolio and a successful "Medtronic Mindset" culture shift, as evidenced by its strong Q3 FY26 results. The company posted impressive organic revenue growth of 5.8% and expanded operating margins, while its robust product pipeline, including Pulsed Field Ablation and the Hugo RAS system, positions it to reclaim market share in key medical technology segments. Despite competitive and regulatory challenges, Medtronic's diversified portfolio, strong leadership, and focus on innovation provide a solid foundation for continued growth and an attractive dividend for investors.
NeuroOne (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne (NMTC) reported its Q1 2026 earnings, detailing a sequential increase in product revenue but a net loss compared to the prior year due to the absence of license revenue. The company highlighted significant progress with its 1RF brain ablation system and trigeminal nerve ablation system, along with advancements in drug delivery and lower back pain programs. NeuroOne also announced a positive fiscal 2026 revenue outlook, projecting at least a 17% increase in sales.
Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Moderate Buy" from Analysts
Analysts have given Boston Scientific Corporation (NYSE:BSX) a consensus "Moderate Buy" rating, with an average 12-month price target of $109.43, despite several firms recently trimming their targets. The company reported strong quarterly earnings, beating EPS estimates and growing revenue by 15.9% year-over-year, and has provided optimistic guidance for Q1 and FY 2026. However, insider selling by the CEO and EVP has occurred, though institutional investors have largely increased their stakes.
Molecular Diagnostics Market is expected to reach US$ 37.19 billion by 2033 | Major key players - Hologic Inc, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, QIAGEN N.V
The global Molecular Diagnostics Market is projected to reach US$ 37.19 billion by 2033, growing at a CAGR of 5.8% from US$ 21.01 billion in 2024. Key market players include Hologic Inc, F. Hoffmann-La Roche Ltd, and Thermo Fisher Scientific Inc. Recent developments in the US and Japan highlight advancements in cancer detection, infectious disease testing, and personalized medicine, driven by new technologies and regulatory approvals.
Penumbra, Inc. (PEN) Stock Analysis: Unveiling a 17.8% Revenue Growth in the Dynamic Medical Devices Sector
Penumbra, Inc. (PEN), a medical devices company, has shown robust revenue growth of 17.80%, highlighting its strong expansion trajectory. Despite an elevated forward P/E ratio, analysts maintain cautiously optimistic ratings, indicating investor confidence in the company's future potential rather than current earnings. Penumbra's diverse product portfolio and reinvestment strategy for growth make it an intriguing opportunity in healthcare technology.
Boston Scientific SCS Lawsuit Filed Over Problems With WaveWriter Alpha System
A product liability lawsuit has been filed against Boston Scientific and the FDA over problems with the WaveWriter Alpha spinal cord stimulator system. The lawsuit claims that the device failed when its lead wires migrated, necessitating surgical removal, and alleges that the FDA failed to adequately screen the device before approving it. The plaintiff, Kenneth Davis, suffered continued pain despite the implant and argues the device was marketed without sufficient independent validation for its design changes.
A Look At Boston Scientific (BSX) Valuation As Electrophysiology Concerns Follow Strong Q4 Earnings
Boston Scientific (BSX) recently reported strong Q4 2025 earnings, but investor focus has shifted to potential stagnation in its U.S. electrophysiology business. Despite a recent share price pullback, various analyses suggest the stock may be undervalued, with a narrative fair value of $108.66 compared to its current price of $74.73. Concerns include tariff headwinds and U.S. reimbursement pressure, while growth drivers are expected from proprietary technologies and successful acquisitions.
Boston Scientific to Acquire Penumbra in $14.5B Deal
Boston Scientific has announced a definitive agreement to acquire Penumbra for approximately $14.5 billion, at $374 per share. This acquisition will expand Boston Scientific's presence in vascular and neurovascular therapies, leveraging Penumbra's portfolio of mechanical thrombectomy and embolization systems. The deal, expected to close in 2026, will be financed with cash and new debt, with shareholders receiving a mix of cash and Boston Scientific stock.
Peering Into Boston Scientific Corp's Recent Short Interest
Boston Scientific Corp's short interest has increased by 20.89% since its last report, with 28.28 million shares currently sold short, representing 1.91% of its tradable shares. At its current trading volume, it would take traders 1.97 days to cover their short positions. Despite the increase, Boston Scientific Corp has less short interest (1.91%) compared to its peers, whose average is 4.57%.
Vanguard Group Inc. Buys 1,115,337 Shares of Boston Scientific Corporation $BSX
Vanguard Group Inc. increased its stake in Boston Scientific Corporation by 0.8% in Q3, acquiring an additional 1,115,337 shares. This brings Vanguard's total ownership to 138,249,447 shares, valued at approximately $13.497 billion and representing 9.33% of the company. Boston Scientific also reported strong Q3 earnings, beating EPS estimates and showing a 15.9% year-over-year revenue increase, with positive guidance for Q1 and FY 2026 despite some analysts lowering price targets.
Capital Planning Advisors LLC Invests $1.45 Million in Boston Scientific Corporation $BSX
Capital Planning Advisors LLC has initiated a new position in Boston Scientific Corporation (NYSE:BSX) by purchasing 14,864 shares valued at approximately $1.45 million in the third quarter. This investment comes amidst notable insider selling by CEO Michael F. Mahoney, who reduced his stake by over 10%, and a "Moderate Buy" consensus rating from analysts with an average price target of $109.43. Boston Scientific also reported strong Q3 results, exceeding EPS estimates and showing significant revenue growth.
Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX
Assetmark Inc. has reduced its holdings in Boston Scientific Corporation (NYSE:BSX) by 41.6%, selling 82,501 shares to hold 115,613 shares worth $11.29 million. Concurrently, Boston Scientific's CEO Michael F. Mahoney also sold 160,901 shares, decreasing his position by over 10%. These transactions occurred amidst various institutional investors either increasing or establishing new positions in the company, showcasing mixed sentiment among investors.
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments
Boston Scientific Corporation (BSX) has maintained its analyst ratings despite price target adjustments by RBC Capital and Bernstein SocGen following its Q4 2025 earnings. The adjustments were primarily due to missed electrophysiology sales and initial 2026 guidance, though the company exceeded overall revenue and EPS consensus. Analysts are looking forward to the CHAMPION‑AF trial results in March as a potential catalyst for the stock.
State of New Jersey Common Pension Fund D Purchases 21,386 Shares of Boston Scientific Corporation $BSX
State of New Jersey Common Pension Fund D increased its stake in Boston Scientific (NYSE:BSX) by 4.3% in the third quarter, acquiring an additional 21,386 shares to reach a total of 517,472 shares valued at $50.52 million. This comes as CEO Michael F. Mahoney and EVP Arthur C. Butcher recently sold significant portions of their holdings. Boston Scientific reported strong Q4 earnings, surpassing EPS estimates with $0.80 and recording a 15.9% year-over-year revenue increase to $5.29 billion.
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments
Boston Scientific Corporation (BSX) has seen its analyst ratings maintained as RBC Capital and Bernstein SocGen both lowered their price targets due to perceived weaknesses in its electrophysiology business and Q4 2025 earnings. Despite these adjustments, analysts remain optimistic, focusing on growth opportunities in electrophysiology through new launches, new data, and ambulatory surgery center expansion, as well as the anticipated CHAMPION-AF trial results in March. The company surpassed revenue and adjusted EPS consensus estimates for Q4 2025, with quarterly revenue reaching $5.29 billion.
Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments
RBC Capital and Bernstein SocGen both lowered their price targets for Boston Scientific Corporation (BSX) to $115 and $112 respectively, while maintaining Outperform ratings. These adjustments followed Boston Scientific's Q4 2025 earnings report, which showed solid overall revenue growth but missed consensus expectations in its electrophysiology and US Watchman sales. Analysts are now closely watching the upcoming CHAMPION‑AF trial results in March as a potential catalyst for the stock.
Aberdeen Group plc Has $257.62 Million Stake in Boston Scientific Corporation $BSX
Aberdeen Group plc increased its stake in Boston Scientific Corporation (NYSE:BSX) by 2.0% during the third quarter, bringing their total holdings to 2,644,944 shares valued at $257.62 million. Other institutional investors like Vanguard Group Inc. and State Street Corp also significantly increased their positions in Boston Scientific. The article also details recent insider stock sales by the company's EVP and CEO, and provides an overview of Boston Scientific's recent financial performance and analyst ratings.
